Brian Stover, M.D.
Assistant Professor
About Brian Stover
Brian Stover, MD, earned his medical degree from the University of Texas Medical School at Houston. Soon after, he began his residency in pediatrics at the University of Florida and continued his career at UF, completing a fellowship in pediatric hematology/oncology.
Dr. Stover joined the UF faculty in 2019 as an assistant professor in the department of pediatrics. His current research focuses on solid tumor immunotherapy, including the use of personalized RNA-nanoparticle vaccines in metastatic osteosarcoma.
Dr. Stover is board-certified in pediatrics by the American Board of Pediatrics and is board-eligible in hematology/oncology. He is a recipient of the Henry A. Kokomoor award for Scientific Discovery and is a member of the American Academy of Pediatrics, the Children’s Oncology Group and the American Society of Pediatric Hematology-Oncology.
Accomplishments
Henry A. Kokomoor Award for Scientific Discovery
2019
·
University of Florida
Pediatric Medical Student Clerkship Excellence in Medical Student Education
2018
·
University of Florida
Pediatric Medical Student Clerkship Excellence in Medical Student Education
2017
·
University of Florida
Pediatric Medical Student Clerkship Excellence in Medical Student Education
2016
·
University of Florida
Pediatric Medical Student Clerkship Excellence in Medical Student Education
2015
·
University of Florida
Board Certifications
-
PediatricsAmerican Board of Pediatrics
Clinical Profile
Specialties
- Pediatrics
Subspecialties
- Pediatric Hematology-Oncology
Areas of Interest
- Bone tumor
- Osteosarcoma
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0003-4349-7881
Areas of Interest
- Personalized RNA-nanoparticle vaccines in metastatic osteosarcoma
- Solid tumor immunotherapy
Publications
Academic Articles
2024
RNA aggregates harness the danger response for potent cancer immunotherapy.
Cell.
187(10):2521-2535.e21
[DOI] 10.1016/j.cell.2024.04.003.
[PMID] 38697107.
2019
Emerging trends in immunotherapy for pediatric sarcomas.
Journal of hematology & oncology.
12(1)
[DOI] 10.1186/s13045-019-0756-z.
[PMID] 31311607.
2018
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Nano letters.
18(10):6195-6206
[DOI] 10.1021/acs.nanolett.8b02179.
[PMID] 30259750.
2016
FGFR1 N546K and H3F3A K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers.
Histopathology.
69(4):704-7
[DOI] 10.1111/his.12983.
[PMID] 27061725.
Grants
Nov 2024
ACTIVE
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via PFIZER INC
Jun 2024
ACTIVE
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Nov 2023
ACTIVE
A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Nov 2023
ACTIVE
A Phase 2 study of SNDX-5613 in combination with chemotherapy for patients with relapsed or refractory KMT2A-rearranged infant leukemia
NCI-2023-00503
NCT05761171
Role: Principal Investigator
Funding: SYNDAX PHARMACEUTICALS
Aug 2023
ACTIVE
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Jul 2023
ACTIVE
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via WWWW FOUNDATION
Apr 2023
ACTIVE
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Oct 2022
ACTIVE
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Aug 2022
ACTIVE
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via LEIDOS
May 2022
ACTIVE
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Apr 2022
ACTIVE
Ultrasound elastogram assessment of liver fibrosis in children and adolescents/young adults (AYA) receiving chemotherapy or allogeneic bone marrow transplantation, and identification of risk factors for liver injury
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jan 2022
ACTIVE
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Jan 2022
– Nov 2024
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)
Role: Principal Investigator
Funding: PUBLIC HLTH INST
via PFIZER INC
Education
Fellowship, Pediatric Hematology/Oncology
2016-2019
·
University of Florida
Residency, Pediatrics
2013-2016
·
University of Florida
Medical School
2008-2013
·
University of Texas Medical School at Houston
Contact Details
Phones:
- Business:
- (352) 273-9120
Emails:
- Business:
- bstover@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100296
GAINESVILLE FL 32610 - Business Street:
-
1600 SW ARCHER RD
GAINESVILLE FL 32610